Presented at the American Society of Pediatric Otolaryngology, Nashville, TN, May 2–6, 2003.
Spastic Diplegia and Other Motor Disturbances in Infants Receiving Interferon-Alpha†
Article first published online: 3 JAN 2009
Copyright © 2004 The Triological Society
Volume 114, Issue 7, pages 1231–1236, July 2004
How to Cite
Michaud, A.-P., Bauman, N. M., Burke, D. K., Manaligod, J. M. and Smith, R. J. H. (2004), Spastic Diplegia and Other Motor Disturbances in Infants Receiving Interferon-Alpha. The Laryngoscope, 114: 1231–1236. doi: 10.1097/00005537-200407000-00017
- Issue published online: 3 JAN 2009
- Article first published online: 3 JAN 2009
- Manuscript Accepted: 16 JAN 2004
- Spastic diplegia;
- motor disturbances;
- neurological complications;
Objective: To determine how frequently the use of -interferon (-IFN) is associated with the development of spastic diplegia.
Study Design and Methods: Meta-analysis of 600 English manuscripts published January 1991 to June 2002 reporting -IFN use in infants/children. We identified 3,113 children 18 years of age or younger and an estimated 3,055 children 12 years of age or younger who received -IFN therapy. Sixty-nine percent were treated for chronic hepatitis and 14% for vascular neoplasms.
Outcome Measure: Neurologic examination to confirm spastic diplegia or a motor developmental disturbance other than spastic diplegia such as hyperactive deep tendon reflexes, gait disturbances, or impaired fine motor control.
Results: Including our index case, 11 of 441 children with vascular lesions developed spastic diplegia and an additional 16 of 441 developed a motor developmental disturbance. All of these children were less than 1 year of age at initiation of therapy. Mean age of initiation and duration of -IFN therapy were not significantly different between groups (P > .05); however, motor developmental disturbances improved with cessation of therapy, whereas spastic diplegia did not. No child receiving treatment for chronic hepatitis developed neurologic complications; however, only 49 children were less than 1 year of age at initiation of therapy.
Conclusion: -IFN should not be used in infants under 1 year of age unless life-threatening conditions do not respond to any other form of treatment. If -IFN must be used, children should have monthly neurologic examinations. If a motor developmental disturbance is detected and -IFN therapy can be discontinued, it should be.